ScholarIQanswers from OpenAlex & ORCID
Hiroshige Yoshioka
ResearcherPublications, citations & collaboration network
Hiroshige Yoshioka is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Hiroshige Yoshioka have?
ScholarIQindexed works
Hiroshige Yoshioka has 357 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Hiroshige Yoshioka have?
ScholarIQcitation count
Hiroshige Yoshioka has 17,187 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Hiroshige Yoshioka?
ScholarIQh-index
Hiroshige Yoshioka has an h-index of 50 in OpenAlex.
What is the i10-index of Hiroshige Yoshioka?
ScholarIQi10-index
Hiroshige Yoshioka has an i10-index of 128 in OpenAlex.
What is the ORCID of Hiroshige Yoshioka?
ScholarIQorcid
The ORCID for Hiroshige Yoshioka is on the source record.
What is the OpenAlex record for Hiroshige Yoshioka?
ScholarIQopenalex
The OpenAlex for Hiroshige Yoshioka is on the source record.
What are the most-cited papers on Hiroshige Yoshioka?
ScholarIQmost cited works
Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo, Young Hak Kim, Koichi Azuma, Takashi Seto, Yuichi Takiguchi, Makoto Nishio, Hiroshige Yoshioka, Fumio Imamura, Katsuyuki Hotta, Satoshi Watanabe, Kōichi Goto, Miyako Satouchi, Toshiyuki Kozuki, Takehito Shukuya, Kazuhiko Nakagawa, Tetsuya Mitsudomi, Nobuyuki Yamamoto, T. Asakawa, Ryoichi Asabe, Tomohiro Tanaka, Tomohide Tamura
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study
Takashi Seto, Katsuyuki Kiura, Makoto Nishio, Kazuhiko Nakagawa, Makoto Maemondo, Akira Inoue, Toyoaki Hida, Nobuyuki Yamamoto, Hiroshige Yoshioka, Masao Harada, Yuichiro Ohe, Naoyuki Nogami, Kengo Takeuchi, Tadashi Shimada, Tomohiro Tanaka, Tomohide Tamura
Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial
Toshiaki Takahashi, Takeharu Yamanaka, Takashi Seto, Hideyuki Harada, Hiroshi Nokihara, Hideo Saka, Makoto Nishio, Hiroyasu Kaneda, Koichi Takayama, Osamu Ishimoto, Koji Takeda, Hiroshige Yoshioka, Motoko Tachihara, Hiroshi Sakai, Kōichi Goto, Nobuyuki Yamamoto
Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC
Byoung Chul Cho, Shun Lu, Enriqueta Felip, Alexander I. Spira, Nicolas Girard, Jong-Seok Lee, Se-Hoon Lee, Yurii Ostapenko, Pongwut Danchaivijitr, Baogang Liu, Adlinda Alip, Ernesto Korbenfeld, Josiane Mourão Dias, Benjamin Besse, Ki-Hyeong Lee, Hailin Xiong, Soon-Hin How, Ying Cheng, Gee‐Chen Chang, Hiroshige Yoshioka, James Chih‐Hsin Yang, Michael J. Thomas, Danny Nguyen, Sai‐Hong Ignatius Ou, Sanjay Mukhedkar, Kumar Prabhash, M. D’Arcangelo, Jorge Alatorre-Alexander, Juan Carlos Vázquez Limón, Sara Alves, Daniil Stroyakovskiy, Marina Peregudova, Mehmet Alı Nahıt Şendur, Ozan Yazıcı, Raffaele Califano, Vanesa Gutiérrez Calderón, Filippo de Marinis, Antonio Passaro, Sang‐We Kim, Shirish M. Gadgeel, John Xie, Tao Sun, Melissa Martínez, Mariah Ennis, E. Fennema, Mahesh Daksh, Dawn Millington, Isabelle Leconte, Ryota Iwasawa, Patricia Lorenzini, Mahadi Baig, Sujay Shah, Joshua Bauml, S. Martin Shreeve, Seema Sethi, R.E. Knoblauch, Hidetoshi Hayashi
Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L
Yoshiko Urata, Nobuyuki Katakami, Satoshi Morita, Reiko Kaji, Hiroshige Yoshioka, Takashi Seto, Miyako Satouchi, Yasuo Iwamoto, Masashi Kanehara, Daichi Fujimoto, Norihiko Ikeda, Haruyasu Murakami, Haruko Daga, Tetsuya Oguri, Isao Goto, Fumio Imamura, Shunichi Sugawara, Hideo Saka, Naoyuki Nogami, Shunichi Negoro, Kazuhiko Nakagawa, Yoichi Nakanishi